Supplemental Figure S3 from Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer
openalex（2023）
Abstract
MET tyrosine kinase domain modeling location of the F1200 residue
Translated text
Key words
ras–mapk pathway limit response,met inhibitor treatment,cancer,met exon,co-occurring,mutation-positive
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined